Business
IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting
Preclinical data demonstrates that gamma-delta T cells have the ability to target other solid tumors such as ovarian cancer, supporting the development of
About this update from In8bio, Inc.
[{"type":"text","content":"Preclinical data demonstrates that gamma-delta T cells have the ability to target other solid tumors such as ovarian cancer, supporting the development of these technologies outside of brain tumorsThe data suggest that INB-400, a clinical stage genetically engineered gamma-delta T cell therapeutic candidate, has the potential to be developed as a novel therapy for ovarian cancer, offering hope for patients with this devastating disease NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, will present preclinical data showcasing the potential of INB-400 to target ovarian cancer at the American Society of Cell & Gene Therapy (ASGCT) Annual Meeting, in Los Angeles from May 16-20, 2023. High-grade serous ovarian cancer (HGSOC) is the most common and devasting form of ovarian cancer, comprising approximately 70-80% of deaths. While poly ADP-ribose polymerase inhibitors (PARPi) have improved patient outcomes, recurrence remains a significant obstacle and unmet medical need. INB-400 is an O6-methylguanine-DNA methyltransferase (MGMT) genetically engineered, chemotherapy resistant gamma-delta T cell product that can recognize and kill cancer cells. INB-400 has shown promising results in preclinical studies, demonstrating a powerful synergistic combination of chemotherapy and gamma-delta T cell therapy to eliminate residual cancer cells. The new data to be presented at ASGCT builds on that success, demonstrating the ability of INB-400 to target and kill multiple ovarian cancer cell lines. \"We believe the technology targeting the DNA damage response pathway underlying our INB-400 program has broad applicability across many solid tumor cancers,” said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. \"These data demonstrate the potential of gamma-delta T cells to target and kill solid tumor cells outside the brain. We are encouraged by these findings and will continue exploring the potential of INB-400 across a broad range of solid tumors where new treatment options are urgently needed.\"Details of the poster presentation are as follows: Abstract Title: Vd2+ Combination Treatment of Temozolomide + PARP Inhibitor Sensitize Ovarian Cancer Cells for Gamma-Delta T Cell Killing Through NKG2DL Expressi...